Curis Stock Earnings Reports
CRIS Upcoming Earnings (Q3 2023)
Earnings Date: | Nov 07, 2023 |
Consensus EPS: | Premium |
Current P/E* ratio: -12.78 | Price (Sep 29, 2023, EOD): $6.59
*The P/E ratio (price-to-earnings ratio) is a financial metric used to assess a company's stock valuation. It is calculated by dividing the stock price by its earnings per share. A higher ratio suggests higher investor expectations, while a lower ratio may indicate undervaluation. It helps investors evaluate potential investments, but it's essential to consider other factors too.
Last 3 Quarters for CRIS Premium
FAQ
About Curis
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize t... CRIS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.